SI2447254T1 - Kristali - Google Patents

Kristali Download PDF

Info

Publication number
SI2447254T1
SI2447254T1 SI201031634T SI201031634T SI2447254T1 SI 2447254 T1 SI2447254 T1 SI 2447254T1 SI 201031634 T SI201031634 T SI 201031634T SI 201031634 T SI201031634 T SI 201031634T SI 2447254 T1 SI2447254 T1 SI 2447254T1
Authority
SI
Slovenia
Prior art keywords
compound
agent
use according
degrees
treatment
Prior art date
Application number
SI201031634T
Other languages
English (en)
Inventor
Hideyuki Itou
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2447254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of SI2447254T1 publication Critical patent/SI2447254T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)

Claims (13)

  1. KRISTALI PATENTNI ZAHTEVKI
    1. Kristal oblike-l 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloksi}-N-(metilsulfonil)acetamida, ki v svojem spektru rentgenske praškovne difrakcije kaže difrakcijske vrhove vsaj pri naslednjih difrakcijskih kotih 2Θ: 9,4 stopinj, 9,8 stopinj, 17,2 stopinj in 19,4 stopinj, kjer se diagram rentgenske praškovne difrakcije dobi z uporabo sevanja Cu Ka.
  2. 2. Farmacevtski sestavek, ki obsega kristal iz zahtevka 1 kot aktivno sestavino.
  3. 3. Agonistično sredstvo PGI2 receptorja, ki obsega kristal iz zahtevka 1 kot aktivno sestavino.
  4. 4. Spojina za uporabo pri zdravljenju diabetične nevropatije, diabetične gangrene, motnje periferne cirkulacije, kronične arterijske okluzije, intermitentne klavdikacije, tromboze, pljučne hipertenzije, miokardnega infarkta, angine, glomerulonefritisa, diabetične nefropatije, kronične ledvične odpovedi, bronhialne astme, intersticijske pnevmonije (pljučne fibroze), skleroderme, kronične obstruktivne pljučne bolezni, vnetne črevesne bolezni, tubulointersticijskega nefritisa ali simptomov, povezanih s stenozo lumbalnega spinalnega kanala, pri čemer je spojina kristal iz zahtevka 1.
  5. 5. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje pljučne hipertenzije.
  6. 6. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje motnje periferne cirkulacije.
  7. 7. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje kronične arterijske okluzije.
  8. 8. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje intermitentne klavdikacije.
  9. 9. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje simptomov, povezanih s stenozo spinalnega kanala.
  10. 10. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje pljučne fibroze.
  11. 11. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje skleroderme.
  12. 12. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje kronične ledvične odpovedi.
  13. 13. Spojina za uporabo po zahtevku 4, kjer je sredstvo za zdravljenje tubulointersticijskega nefritisa.
SI201031634T 2009-06-26 2010-06-25 Kristali SI2447254T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009151727 2009-06-26
JP2009151728 2009-06-26
JP2009151729 2009-06-26
EP10792183.5A EP2447254B1 (en) 2009-06-26 2010-06-25 Crystals
PCT/JP2010/060798 WO2010150865A1 (ja) 2009-06-26 2010-06-25 結晶

Publications (1)

Publication Number Publication Date
SI2447254T1 true SI2447254T1 (sl) 2018-03-30

Family

ID=43386634

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031634T SI2447254T1 (sl) 2009-06-26 2010-06-25 Kristali
SI201031997T SI3275871T1 (sl) 2009-06-26 2010-06-25 Kristali

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201031997T SI3275871T1 (sl) 2009-06-26 2010-06-25 Kristali

Country Status (33)

Country Link
US (4) US8791122B2 (sl)
EP (3) EP2447254B1 (sl)
JP (1) JPWO2010150865A1 (sl)
KR (1) KR20170024165A (sl)
CN (2) CN104326991A (sl)
AR (1) AR077242A1 (sl)
AU (1) AU2010263569B2 (sl)
BR (2) BR122021005510B1 (sl)
CA (1) CA2764475C (sl)
CL (1) CL2011003264A1 (sl)
CO (1) CO6430432A2 (sl)
CY (3) CY1119788T1 (sl)
DK (2) DK2447254T3 (sl)
ES (2) ES2797124T3 (sl)
HK (1) HK1244788A1 (sl)
HR (2) HRP20180171T1 (sl)
HU (3) HUE048467T2 (sl)
IL (3) IL216928A (sl)
LT (3) LT3275871T (sl)
MA (1) MA33637B1 (sl)
MX (2) MX2011013471A (sl)
MY (1) MY186531A (sl)
NO (2) NO2447254T3 (sl)
NZ (1) NZ597352A (sl)
PH (2) PH12015502825B1 (sl)
PL (2) PL2447254T3 (sl)
PT (2) PT2447254T (sl)
RU (1) RU2556206C3 (sl)
SG (2) SG10201403313WA (sl)
SI (2) SI2447254T1 (sl)
TW (1) TWI531565B (sl)
WO (1) WO2010150865A1 (sl)
ZA (1) ZA201109099B (sl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959868A (zh) * 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
WO2010010909A1 (ja) * 2008-07-23 2010-01-28 東レ株式会社 慢性腎不全処置剤
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
WO2017040872A1 (en) 2015-09-03 2017-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
CN108289890B (zh) * 2015-12-02 2021-04-27 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
WO2017168401A1 (en) * 2016-04-01 2017-10-05 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
US10544107B2 (en) 2016-07-05 2020-01-28 Maithri Drugs Private Limited Process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN111093704A (zh) 2017-07-27 2020-05-01 阿勒根公司 用于减少身体脂肪的前列环素受体激动剂
UA126928C2 (uk) * 2017-09-28 2023-02-22 Ніппон Сіняку Ко., Лтд. Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилоксі}оцтової кислоти
WO2019098300A1 (ja) 2017-11-16 2019-05-23 日本新薬株式会社 放出制御製剤
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
CN111699175B (zh) 2018-02-07 2022-03-29 南京明德新药研发有限公司 前列环素受体受体激动剂
MA51913A (fr) * 2018-02-21 2020-12-30 Nippon Shinyaku Co Ltd Composition granulaire, procédé de production d'une composition granulaire et procédé d'amélioration de la propriété d'élution d'une composition granulaire
CN109125325B (zh) * 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
US20220331313A1 (en) 2019-05-06 2022-10-20 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
US20220257594A1 (en) 2019-05-21 2022-08-18 Actelion Pharmaceuticals Ltd Transitioning patients treated for pulmonary arterial hypertension to selexipag
EP3982967A1 (en) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
PE20221455A1 (es) 2019-10-23 2022-09-21 Actelion Pharmaceuticals Ltd Composicion farmaceutica que comprende selexipag
IL293271A (en) 2019-11-29 2022-07-01 Actelion Pharmaceuticals Ltd Methods for treating pulmonary artery hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
WO2021156227A1 (en) 2020-02-03 2021-08-12 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067748A1 (fr) 1999-05-10 2000-11-16 Toray Industries, Inc. Remèdes à l'insuffisance rénale
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
ATE260281T1 (de) 2000-08-03 2004-03-15 Pfizer Prod Inc Diazacyclooctanverbindungen und ihre therapeutische verwendung
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
TWI316055B (sl) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
EP1642584A1 (en) 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd External preparation for improving coital function
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
CN101959868A (zh) 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
CA2728089C (en) 2008-06-23 2017-04-11 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
WO2010010909A1 (ja) 2008-07-23 2010-01-28 東レ株式会社 慢性腎不全処置剤
KR101645752B1 (ko) 2008-09-10 2016-08-04 아사히 가라스 가부시키가이샤 신규의 프로스타글란딘 ｉ2 유도체

Also Published As

Publication number Publication date
CY2018011I2 (el) 2018-09-05
US20120101276A1 (en) 2012-04-26
MY186531A (en) 2021-07-25
IL216928A (en) 2016-10-31
ZA201109099B (en) 2012-08-29
CL2011003264A1 (es) 2012-07-06
PT3275871T (pt) 2020-04-21
US8791122B2 (en) 2014-07-29
ES2660007T3 (es) 2018-03-20
PH12015502824A1 (en) 2017-05-29
CA2764475C (en) 2017-04-25
EP3275871A1 (en) 2018-01-31
TW201111352A (en) 2011-04-01
TWI531565B (zh) 2016-05-01
HRP20180171T1 (hr) 2018-03-09
DK3275871T3 (da) 2020-04-06
CA2764475A1 (en) 2010-12-29
US20140155414A1 (en) 2014-06-05
ES2797124T3 (es) 2020-12-01
HUE036721T2 (hu) 2018-07-30
EP2447254B1 (en) 2017-12-06
HUS1800015I1 (hu) 2018-05-28
IL243287B (en) 2021-04-29
AR077242A1 (es) 2011-08-10
EP3275871B1 (en) 2020-01-15
AU2010263569B2 (en) 2016-08-18
SI3275871T1 (sl) 2020-06-30
JPWO2010150865A1 (ja) 2012-12-10
BRPI1015936A2 (pt) 2016-08-16
NZ597352A (en) 2013-01-25
NO2447254T3 (sl) 2018-05-05
AU2010263569A1 (en) 2012-02-02
RU2556206C2 (ru) 2015-07-10
PL2447254T3 (pl) 2018-05-30
DK2447254T3 (en) 2018-01-15
BRPI1015936B1 (pt) 2021-07-13
HK1244788A1 (zh) 2018-08-17
PT2447254T (pt) 2018-01-04
LTC2447254I2 (lt) 2022-04-25
MX346318B (es) 2017-03-15
RU2012102678A (ru) 2013-08-10
CY1122893T1 (el) 2021-05-05
EP3689855A1 (en) 2020-08-05
MX2011013471A (es) 2012-01-30
US9440931B2 (en) 2016-09-13
US8791122C1 (sl) 2014-07-29
LT2447254T (lt) 2018-01-10
LT3275871T (lt) 2020-05-11
SG10201403313WA (en) 2014-10-30
IL243287A0 (en) 2016-02-29
NO2018015I1 (no) 2018-04-23
KR20120109457A (ko) 2012-10-08
US9284280B2 (en) 2016-03-15
CY1119788T1 (el) 2018-06-27
PH12015502825A1 (en) 2017-12-11
PH12015502825B1 (en) 2017-12-11
EP2447254A4 (en) 2012-12-19
EP2447254A1 (en) 2012-05-02
US9340516B2 (en) 2016-05-17
BR122021005510B1 (pt) 2022-01-11
CO6430432A2 (es) 2012-04-30
LTPA2018008I1 (lt) 2018-05-10
MA33637B1 (fr) 2012-10-01
CN102459198B (zh) 2014-09-24
IL216928A0 (en) 2012-02-29
KR20170024165A (ko) 2017-03-06
CN104326991A (zh) 2015-02-04
HUE048467T2 (hu) 2020-07-28
US20140148469A1 (en) 2014-05-29
WO2010150865A1 (ja) 2010-12-29
US20150266830A1 (en) 2015-09-24
PL3275871T3 (pl) 2020-07-27
CY2018011I1 (el) 2018-09-05
HRP20200539T1 (hr) 2020-07-10
IL243293A0 (en) 2016-02-29
CN102459198A (zh) 2012-05-16
SG176915A1 (en) 2012-01-30
RU2556206C3 (ru) 2021-06-15

Similar Documents

Publication Publication Date Title
SI2447254T1 (sl) Kristali
EA201000384A1 (ru) Новая полиморфная форма ротиготина и способ её получения
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
HRP20140274T1 (hr) Farmaceutske kombinacije od antagonista receptora angiotenzina i nep-inhibitora
JP2015145426A5 (sl)
JP2019142893A5 (sl)
RU2018123304A (ru) Фармацевтическая композиция, содержащая 2-{ 4-[n-(5,6-дифенилпиразин-2-ил)-n-изопропиламино]бутилокси} -n-(метилсульфонил)ацетамид
JP2016065042A5 (sl)
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
JP2015514060A5 (sl)
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
WO2010103547A3 (en) Substituted fused pyrimidine compounds
JP2012531408A5 (sl)
Maddileti et al. Tetramorphs of the antibiotic drug trimethoprim: characterization and stability
EA201101304A1 (ru) Новая кристаллическая форма vi агомелатина, ее получение и применение
RU2008141373A (ru) Соль алискирена и серной кислоты
JP2007520539A (ja) カンナビノイド受容体モジュレーターとしてのピリジン誘導体
RU2019123404A (ru) Производное пиримидина
RU2013103754A (ru) Новые кристаллические формы n-[-2[[(2,3,-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азатидин-сульфонамида
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
RU2016116274A (ru) Твёрдые формы цефтолозана
RU2020112117A (ru) Кристаллическое вещество
JP2013541589A5 (sl)
JP2013501072A5 (sl)